Patient Recruitment and Retention in Clinical Trials

28th & 29th October 2008, Hyatt Regency at Penn's Landing, Philadelphia, PA
Patient recruitment and retention is the leading problem drug companies face in developing their new pipelines. As recruiting becomes more diverse and complex, pharmaceutical companies are striving to discover new innovative ways to facilitate recruitment and keep patients enrolled in the clinical trial. With more and more clinical trials being done on a global level, it is imperative to have an understanding of government regulations as well as social protocol that accompany these new markets. This five star conference will present you with the opportunity to network and benchmark with your industry peers. This event will bring together senior level experts from pharmaceutical companies to benchmark best practices and success stories. Join them to hear practical advice on patient recruitment and retention strategies. Take home valuable know-how that can help you master day to day tasks and draft a strategy to take you to the next level.

Key Speakers:
Patient Recruitment Specialist, MERCK
Clinical Program Director, Global Clinical Lead, UCB
Senior CRA, DAIICHI SANKYO
Director Feasibility and Patient Recruitment, AMGEN
Patient/Compliance Strategist-Operations, SANOFI-AVENTIS
Senior Marketing Director, ROCHE
Associate Director, UCB

Key Topics:

  • Develop new and innovative ways to reach patients
  • Understand key issues regarding patient recruitment in a global market
  • Improve public perception of clinical trials
  • Network with the industry's top patient recruitment professionals

For further information and registration please visit:
http://www.jacobfleming.com/conferences/life-science/patient-recruitment

About Jacob Fleming Group
Jacob Fleming Group is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech Republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors. For more information, visit www.jacobfleming.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...